A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

• ABI-6250 (Drug): Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
• Placebo (Drug): Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Primary outcomes

• Proportion of subjects with AEs, premature treatment discontinuation due to AEs and abnormal laboratory results [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Area Under the Plasma Concentration Time Curve (AUC) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Maximum Observed Plasma Concentration (Cmax) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Time to Cmax (Tmax) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Apparent Systemic Clearance (CL/F) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Apparent Volume of Distribution (Vz/F) of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Dose normalized AUCs and Cmax of ABI-6250 [From enrollment to 10 days after the last dose, at pre-specified timepoints]

Secondary outcomes

• Comparison of plasma AUC between fasted and fed treatments [From enrollment to 10 days after the last dose, at pre-specified timepoints]
• Comparison of AUC between fasted and fed treatments [From enrollment to 10 days after the last dose, at pre-specified timepoints]

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria:

* Participant has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2 and is in good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
* Female participants must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose).
* Participants must agree to comply with protocol-specified contraceptive requirements.

Exclusion Criteria:

* Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV) or acute hepatitis A virus (HAV).
* History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs.
* History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies.
* History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening.
* Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer.